Title:
Ｎ−（１−（（２−（ジメチルアミノ）エチル）アミノ）−２−メチル−１−オキソプロパン−２−イル）−４−（４−（２−メチル−５−（（２Ｓ，３Ｒ，４Ｒ，５Ｓ，６Ｒ）−３，４，５−トリヒドロキシ−６−（メチルチオ）テトラヒドロ−２Ｈ−ピラン−２−イル）ベンジル）フェニル）ブタンアミドの結晶形態及びそれらの合成方法
Document Type and Number:
Japanese Patent JP2022502393
Kind Code:
A
Abstract:
Ｎ−（１−（（２−（ジメチルアミノ）エチル）アミノ）−２−メチル−１−オキソプロパン−２−イル）−４−（４−（２−メチル−５−（（２Ｓ，３Ｒ，４Ｒ，５Ｓ，６Ｒ）−３，４，５−トリヒドロキシ−６−（メチルチオ）テトラヒドロ−２Ｈ−ピラン−２−イル）ベンジル）フェニル）ブタンアミド並びにその塩、溶媒和物及び共結晶の固体形態の作製方法と該固体形態とが開示される。【選択図】なし
Inventors:
Bedners Mark Steven
Dai Quanchu
Eckert Geoffrey Manning
Rim Gap-Key
Shirois Lauren
Wu Wen Shue
Jao Matthew Manju
Dai Quanchu
Eckert Geoffrey Manning
Rim Gap-Key
Shirois Lauren
Wu Wen Shue
Jao Matthew Manju
Application Number:
JP2021516806A
Publication Date:
January 11, 2022
Filing Date:
September 23, 2019
Export Citation:
Assignee:
Rexicon Pharmaceuticals, Inc.
International Classes:
C07H7/04; A61K31/7004; A61P3/00; A61P3/10; A61P43/00; C07C237/10; C07D309/12; C07F5/04; C07H7/02
Domestic Patent References:
| JP2016504285A | 2016-02-12 | |||
| JP2004536047A | 2004-12-02 | |||
| JP4759102B2 | 2011-08-31 | |||
| JP2014513693A | 2014-06-05 |
Other References:
TILBORG, A. ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 74, JPN6021017265, 2014, pages 411 - 426, ISSN: 0004989458
Attorney, Agent or Firm:
Patent Business Corporation Saegusa International Patent Office
Previous Patent: Method for manufacturing oral dosage form
Next Patent: Synergistic effect of helminthic treatment
Next Patent: Synergistic effect of helminthic treatment